/TSVT
TSVT Stock - 2seventy bio, Inc.
Healthcare|BiotechnologyNASDAQ
$5.00+0.00%
+$0.00 (+0.00%) • May 13
63
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.80
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).50
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.78
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+0.0%upside
Target: $5.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TSVT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.95 – $5.05
TARGET (TP)$5.00
STOP LOSS$4.60
RISK/REWARD1:0.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.05
52W High$5.30
52W Low$2.29
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $37.86M | $100.39M | $91.50M | $54.52M | $248.12M |
| Gross Profit | $15.30M | $83.47M | $65.28M | $41.93M | $242.73M |
| Gross Margin | 40.4% | 83.1% | 71.3% | 76.9% | 97.8% |
| Operating Income | $-115,430,000 | $-237,608,000 | $-262,908,000 | $-313,509,000 | $-144,638,000 |
| Net Income | $-57,247,000 | $-217,570,000 | $-254,144,013 | $-276,214,000 | $-138,170,000 |
| Net Margin | -151.2% | -216.7% | -277.8% | -506.6% | -55.7% |
| EPS | $-1.10 | $-4.42 | $-7.13 | $-11.71 | $-5.93 |
Company Overview
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
50%
Hold / Neutral
3
38%
Sell / Underperform
1
13%
Analyst Consensus🟡 Mixed
4 Bullish4 Neutral/Bearish
Price Targets
$14
Average Target
↑ 182.5% Upside
Now
$2
Low
$14
Average
$30
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 6th 2024 | Goldman | Downgrade | Sell | $2← $5 |
| January 31st 2024 | TD Cowen | Downgrade | Market Perform | - |
| January 31st 2024 | Leerink Partners | Upgrade | Outperform | $18← $5 |
| October 30th 2023 | Leerink Partners | Downgrade | Market Perform | $6 |
| October 12th 2023 | Citigroup | Initiation | Buy | $13 |
| September 13th 2023 | Goldman | Downgrade | Neutral | $5 |
| September 12th 2023 | Guggenheim | Downgrade | Neutral | - |
| July 28th 2023 | Morgan Stanley | Downgrade | Equal Weight | $13← $25 |
| October 31st 2022 | Guggenheim | Initiation | Buy | $30 |
| May 2nd 2022 | Goldman | Initiation | Buy | $26 |
Earnings History & Surprises
TSVTBeat Rate
60%
Last 15 quarters
Avg Surprise
+5.7%
EPS vs Estimate
Beats / Misses
9/6
Last 12 quarters
Latest EPS
$0.01
Q2 2025
EPS Surprise History
Q3 23
+20.2%
$-0.83vs$-1.04
Q4 23
+23.7%
$-1.00vs$-1.31
Q1 24
+9.0%
$-1.11vs$-1.22
Q2 24
-12.5%
$-0.81vs$-0.72
Q3 24
+17.1%
$-0.29vs$-0.35
Q4 24
-28.6%
$-0.18vs$-0.14
Q1 25
-34.8%
$-0.31vs$-0.23
Q2 25
+105.9%
$0.01vs$-0.17
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 10, 2025 | — | — | — | — |
Q3 2025 | Aug 6, 2025 | $-0.05 | — | — | — |
Q2 2025 | May 7, 2025 | $-0.17 | $0.01 | +105.9% | ✓ BEAT |
Q1 2025 | Mar 25, 2025 | $-0.23 | $-0.31 | -34.8% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.14 | $-0.18 | -28.6% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.35 | $-0.29 | +17.1% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.72 | $-0.81 | -12.5% | ✗ MISS |
Q1 2024 | Mar 5, 2024 | $-1.22 | $-1.11 | +9.0% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-1.31 | $-1.00 | +23.7% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-1.04 | $-0.83 | +20.2% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $-1.19 | $-1.08 | +9.2% | ✓ BEAT |
Q1 2023 | Mar 16, 2023 | $-1.53 | $-0.60 | +60.8% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-1.74 | $-1.76 | -1.1% | ✗ MISS |
Q3 2022 | Aug 10, 2022 | $-2.08 | $-2.02 | +2.9% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-1.73 | $-3.20 | -85.0% | ✗ MISS |
Q1 2022 | Mar 22, 2022 | $-2.45 | $-2.55 | -4.1% | ✗ MISS |
Q4 2021 | Dec 1, 2021 | $-2.71 | $-2.62 | +3.3% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | — | $-3.61 | — | — |
Q2 2021 | May 11, 2021 | — | $-3.30 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-3.74 | — | — |
Latest News
Loading news...
Frequently Asked Questions about TSVT
What is TSVT's current stock price?
2seventy bio, Inc. (TSVT) is currently trading at $5.00 per share. The stock has moved +0.00% today.
What is the analyst price target for TSVT?
The average analyst price target for TSVT is $5.00, based on 1 analyst.
What sector is 2seventy bio, Inc. in?
2seventy bio, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TSVT's market cap?
2seventy bio, Inc. has a market capitalization of $0.27 billion, making it a small-cap company.
Does TSVT pay dividends?
No, 2seventy bio, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCATB
Catabasis Pharmaceuticals, Inc.
$8.54
Mkt Cap: $0.2B
CRGX
CARGO Therapeutics, Inc. Common Stock
$4.47
Mkt Cap: $0.2B
INZY
Inozyme Pharma, Inc.
$4.00
Mkt Cap: $0.3B
LFCR
Lifecore Biomedical, Inc.
$8.04
Mkt Cap: $0.3B
MACK
Merrimack Pharmaceuticals, Inc.
$15.14
Mkt Cap: $0.2B
SCPH
scPharmaceuticals Inc.
$5.67
Mkt Cap: $0.3B
SLRN
Acelyrin, Inc.
$2.27
Mkt Cap: $0.2B
SPPI
Spectrum Pharmaceuticals, Inc.
$1.02
Mkt Cap: $0.2B
TCRT
Alaunos Therapeutics, Inc.
$3.56
Mkt Cap: $0.0B
THRD
Third Harmonic Bio, Inc.
$5.38
Mkt Cap: $0.2B
Explore stocks similar to TSVT for comparison